Axsome Therapeutics - AXSM Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

12 brokers have issued 1-year price targets for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $75.00 to $210.00. On average, they expect the company's stock price to reach $108.15 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 10.9% and is now trading at $68.70.
View the best growth stocks for 2023 here.

Axsome Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 7,940,000 shares, an increase of 5.2% from the December 31st total of 7,550,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 5.9 days. Approximately 22.4% of the company's shares are short sold.
View Axsome Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our AXSM earnings forecast.

Axsome Therapeutics will be holding an earnings conference call on Monday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings data on Monday, November, 7th. The company reported ($1.03) EPS for the quarter, beating analysts' consensus estimates of ($1.10) by $0.07. The firm had revenue of $16.85 million for the quarter, compared to analysts' expectations of $16.59 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Axsome Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell & Co. (0.85%), Iridian Asset Management LLC CT (0.73%), Simplex Trading LLC (0.00%), Peregrine Capital Management LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.21%) and Lindbrook Capital LLC (0.19%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs.
View institutional ownership trends.

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXSM stock can currently be purchased for approximately $68.70.

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $2.98 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis.

The company employs 108 workers across the globe.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.